2018
Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial
Leira EC, Viscoli CM, Polgreen LA, Gorman M, Kernan WN. Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. Neuroepidemiology 2018, 50: 137-143. PMID: 29587267, PMCID: PMC5975097, DOI: 10.1159/000486315.Peer-Reviewed Original ResearchConceptsPerson visitsStroke trialsTreatment adherenceStudy centersInsulin Resistance InterventionLogistic regression modelsIndependent predictorsPreventive careClinical trialsOutcome measuresThird visitPatientsPlace of residenceResistance InterventionSecondary analysisYears of participationVisitsAdherenceGeneralizability of resultsTrialsRural areasTherapyDrugsRegression modelsRecruitment sites
2005
Altruism as a reason for participation in clinical trials was independently associated with adherence
Rosenbaum JR, Wells CK, Viscoli CM, Brass LM, Kernan WN, Horwitz RI. Altruism as a reason for participation in clinical trials was independently associated with adherence. Journal Of Clinical Epidemiology 2005, 58: 1109-1114. PMID: 16223653, DOI: 10.1016/j.jclinepi.2005.03.014.Peer-Reviewed Original ResearchConceptsClinical trialsBetter functional statusStudy medicationMedical regimenRecruitment of participantsClinical featuresStroke trialsFunctional statusWomen's EstrogenStratified analysisMultivariable regressionClinical researchEstrogenTrialsAdherenceBaseline featuresSocial supportFurther investigationWomenParticipantsAltruistic reasonsPossible contributionHigh levelsPlaceboMedications
1990
Treatment adherence and risk of death after a myocardial infarction
Horwitz RI, Viscoli CM, Donaldson R, Murray C, Ransohoff D, Horwitz R, Berkman L, Horwitz S, Ransohoff D, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. The Lancet 1990, 336: 542-545. PMID: 1975045, DOI: 10.1016/0140-6736(90)92095-y.Peer-Reviewed Original ResearchConceptsRisk of deathTreatment adherenceMyocardial infarctionPoor adherersBeta-Blocker Heart Attack TrialPost-infarction mortalityHeart Attack TrialGood adherersTreatment regimenAttack TrialClinical severitySociodemographic featuresInfarctionAdherersAdherenceDeathMortalityRiskSeverityPlaceboRegimenSmokingPatientsPropranololTrials